

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7726023

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the NAME OF THE ASSIGNOR FROM WU, BIN TO PHOSPHOREX, INC. previously recorded on Reel 061531 Frame 0199. Assignor(s) hereby confirms the NAME OF THE ASSIGNOR IS PHOSPHOREX, INC..

CONVEYING PARTY DATA

Name	Execution Date
PHOSPHOREX, INC.	08/18/2022

RECEIVING PARTY DATA

Name:	CYTODIGM, INC.
Street Address:	7 SOLOMON ROAD
City:	LEXINGTON
State/Country:	MASSACHUSETTS
Postal Code:	02429

PROPERTY NUMBERS Total: 17

Property Type	Number
Application Number:	14573212
Application Number:	16040640
Application Number:	17470163
Application Number:	17677313
Application Number:	17858404
Application Number:	16887835
Application Number:	17065823
Application Number:	17215565
Application Number:	62478317
Application Number:	16582688
Application Number:	16986526
Application Number:	63115695
Application Number:	63153479
Application Number:	62780485
PCT Number:	US2021060105
PCT Number:	US2018025075
PCT Number:	US2013046981

CORRESPONDENCE DATA**Fax Number:**

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6174496500
Email: cgiordani@mccarter.com
Correspondent Name: YU LU, PH.D.
Address Line 1: 265 FRANKLIN STREET
Address Line 2: MCCARTER ENGLISH LLP
Address Line 4: BOSTON, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER:	122394-00001
NAME OF SUBMITTER:	YU LU, PH.D
SIGNATURE:	/Yu Lu/
DATE SIGNED:	01/05/2023

Total Attachments: 15

source=Corrected Notice of Recordation Phosphorex to Cytodigm_122394-00001#page1.tif
source=Corrected Notice of Recordation Phosphorex to Cytodigm_122394-00001#page2.tif
source=Corrected Notice of Recordation Phosphorex to Cytodigm_122394-00001#page3.tif
source=Corrected Notice of Recordation Phosphorex to Cytodigm_122394-00001#page4.tif
source=Corrected Notice of Recordation Phosphorex to Cytodigm_122394-00001#page5.tif
source=Corrected Notice of Recordation Phosphorex to Cytodigm_122394-00001#page6.tif
source=Corrected Notice of Recordation Phosphorex to Cytodigm_122394-00001#page7.tif
source=Corrected Notice of Recordation Phosphorex to Cytodigm_122394-00001#page8.tif
source=Corrected Notice of Recordation Phosphorex to Cytodigm_122394-00001#page9.tif
source=Corrected Notice of Recordation Phosphorex to Cytodigm_122394-00001#page10.tif
source=Corrected Notice of Recordation Phosphorex to Cytodigm_122394-00001#page11.tif
source=Corrected Notice of Recordation Phosphorex to Cytodigm_122394-00001#page12.tif
source=Corrected Notice of Recordation Phosphorex to Cytodigm_122394-00001#page13.tif
source=Corrected Notice of Recordation Phosphorex to Cytodigm_122394-00001#page14.tif
source=Corrected Notice of Recordation Phosphorex to Cytodigm_122394-00001#page15.tif

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BIN WU	08/18/2022
RECEIVING PARTY DATA	
Name:	CYTODIGM, INC.
Street Address:	7 SOLOMON ROAD
City:	LEXINGTON
State/Country:	MASSACHUSETTS
Postal Code:	02429
PROPERTY NUMBERS Total: 17	
Property Type	Number
Application Number:	14573212
Application Number:	16040640
Application Number:	17470163
Application Number:	17677313
Application Number:	17858404
PCT Number:	US2021060105
PCT Number:	US2018025075
PCT Number:	US2013046981
Application Number:	16887835
Application Number:	17065823
Application Number:	17215565
Application Number:	62478317
Application Number:	16582688
Application Number:	16986526
Application Number:	63115695
Application Number:	63153479
Application Number:	62780485

CORRESPONDENCE DATA

Fax Number:

Email: kmuzarol@Mccarter.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Correspondent Name: YU LU

Address Line 1: MCCARTER & ENGLISH, LLP

Address Line 4: BOSTON, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER:	122394-00001
--------------------------------	--------------

NAME OF SUBMITTER:	YU LU
---------------------------	-------

Signature:	/ Yu Lu /
-------------------	-----------

Date:	10/25/2022
--------------	------------

Total Attachments: 10

source=Phosphorex-Cytodigm Assignment Executed 122394-00001#page1.tif
source=Phosphorex-Cytodigm Assignment Executed 122394-00001#page2.tif
source=Phosphorex-Cytodigm Assignment Executed 122394-00001#page3.tif
source=Phosphorex-Cytodigm Assignment Executed 122394-00001#page4.tif
source=Phosphorex-Cytodigm Assignment Executed 122394-00001#page5.tif
source=Phosphorex-Cytodigm Assignment Executed 122394-00001#page6.tif
source=Phosphorex-Cytodigm Assignment Executed 122394-00001#page7.tif
source=Phosphorex-Cytodigm Assignment Executed 122394-00001#page8.tif
source=Phosphorex-Cytodigm Assignment Executed 122394-00001#page9.tif
source=Phosphorex-Cytodigm Assignment Executed 122394-00001#page10.tif

RECEIPT INFORMATION

EPAS ID: PAT7609198

Receipt Date: 10/25/2022

ASSIGNMENT, TRANSFER, AND ASSUMPTION AGREEMENT

August 18, 2022

THIS ASSIGNMENT, TRANSFER, AND ASSUMPTION AGREEMENT (this “**Agreement**”) is entered into by and between Phosphorex, Inc., a Massachusetts corporation (“**Transferor**”), and Cytodigm, Inc., a Delaware corporation (“**Transferee**”), as of the date set forth above (the “**Effective Date**”). Transferor and Transferee may each be referred to hereinafter as a “**Party**” and, collectively, as the “**Parties**”.

WHEREAS, Transferor owns the intellectual property assets listed on Exhibit A hereto (the “**Assigned Intellectual Property**”);

WHEREAS, Transferor desires to transfer, convey, grant, and assign to Transferee, and Transferee desires to accept, assume, and obtain from Transferor, all of Transferor’s right, title, and interest in and to the Assigned Intellectual Property in accordance with the terms of this Agreement; and

WHEREAS, as of the Effective Date, Transferor is a qualified Subchapter S subsidiary of the Transferee within the meaning of Section 1361(b)(3)(B) of the Internal Revenue Code of 1986, as amended (the “Code”).

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1. Transfers and Assignments.

a) Assigned Intellectual Property. On the terms and subject to the conditions set forth in this Agreement, Transferor hereby irrevocably and unconditionally transfers, grants, sells, conveys and assigns to Transferee, as of the Effective Date, and Transferee hereby irrevocably assumes and accepts, all of Transferor’s right, title and interest in and to the Assigned Intellectual Property to be held and enjoyed by Transferee for its own use and benefit and for its successors, legal representatives and assigns, as the same would have been held as fully and entirely by Transferor had this assignment not been made.

b)

c)

2.

3. Miscellaneous.

- a) Governing Law. This Agreement is to be construed, interpreted, applied and governed in all respects in accordance with the laws of the State of Delaware, without regard to any conflict of laws provisions that would require the application of the laws of any other jurisdiction.
- b) Successors and Assigns. This Agreement is binding upon and shall inure to the benefit of the Parties and their respective successors and assigns.
- c) Entire Agreement; Assignment; Third Party Beneficiaries. This Agreement represents the complete understanding and agreement between the Parties with respect to the subject matter hereof. This Agreement may be canceled, modified, waived or amended only by a written instrument executed by each of the Parties. Except as expressly contemplated hereby, there are no third party beneficiaries to this Agreement.
- d) Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
- e) Headings. The section headings of this Agreement are for the convenience of the Parties only and in no way alter, modify, amend, limit, or restrict the contractual obligations of the Parties.
- f) Severability; Waiver. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision. Waiver by either Party or the failure by either Party to claim a breach of any provision of this Agreement shall not be deemed to constitute a waiver or estoppel with respect to any subsequent breach of any provision hereof.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

The parties hereto have caused this Agreement to be executed and delivered as of the date set forth above.

PHOSPHOREX, INC.

DocuSigned by:

Bin Wu

6856938CF6DE4D4...

Name: Bin Wu, Ph.D.

Title: Authorized Signatory

CYTODIGM, INC.

DocuSigned by:

Bin Wu

6856938CF6DE4D4...

By: _____

Name: Bin Wu, Ph.D.

Title: President

[Signature Page to Assignment, Transfer, and Assumption Agreement]

ACTIVE/118562668.3NB31 141325-351484

PATENT
REEL: 062296 FRAME: 0102

EXHIBIT A: ASSIGNED INTELLECTUAL PROPERTY**Patents:**

Case Number	Country	Case Type	Application Status	Application Number	Filing Date	Patent Number	Issue Date
NANOPARTICLES OF INDIRUBIN, DERIVATIVES THEREOF AND METHODS OF MAKING AND USING SAME							
122394-00302	US	CON	Granted	14/573212	17-Dec-2014	10039829	07-Aug-2018
122394-00303	US	DIV	Granted	16/040640	20-Jul-2018	10675350	09-Jun-2020
122394-00304	US	CON	Abandoned	16/887835	29-May-2020		
122394-00305	US	CON	Abandoned	17/065823	08-Oct-2020		
122394-00306	US	CON	Abandoned	17/215505	29-Mar-2021		
122394-00307	US	CON	Published	17/470163	09-Sep-2021		
122394-00308	US	CON	Pending	17/677313	22-Feb-2022		
122394-00320	WO	ORD	Completed	PCT/US2013/046981	21-Jun-2013		
122394-00326	CA	PCT	Granted	2914782	08-Dec-2015	2914782	25-May-2021
122394-00328	CN	PCT	Granted	201380043697.4	16-Feb-2015	ZL201380043697.4	28-Jun-2019
122394-00335	EP	PCT	Granted	13806153.6	21-Jan-2015	2863897	19-Jun-2019
122394-00343	JP	PCT	Granted	2015-518599	18-Dec-2014	6382187	10-Aug-2018
122394-00371	JP	DIV	Abandoned	2020-001832	19-Jan-2020		
122394-00377	JP	DIV	Abandoned	2018-144837	01-Aug-2018		
122394-00378	CN	DIV	Published	201910470369.1	31-May-2019		

Case Number	Country	Case Type	Application Status	Application Number	Filing Date	Patent Number	Issue Date
122394-00379	EP	DIV	Published	19180122.4	13-Jun-2019		
122394-00385	FR	EPP	Granted	13806153.6	21-Jan-2015	2863897	19-Jun-2019
122394-00386	GB	EPP	Granted	13806153.6	21-Jan-2015	2863897	19-Jun-2019
122394-00387	CH	EPP	Granted	13806153.6	21-Jan-2015	2863897	19-Jun-2019
122394-00388	JP	DIV	Published	2021-118361	19-Jul-2021		
122394-00389	IE	EPP	Granted	13806153.6	21-Jan-2015	2863897	19-Jun-2019
122394-00393	NL	EPP	Granted	13806153.6	21-Jan-2015	2863897	19-Jun-2019
122394-00395	DE	EPP	Granted	13806153.6	21-Jan-2015	602013056868.5	19-Jun-2019
122394-00397	BE	EPP	Granted	13806153.6	21-Jan-2015	2863897	19-Jun-2019
122394-00398	SE	EPP	Granted	13806153.6	21-Jan-2015	2863897	19-Jun-2019
NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME							
122394-00601	US	PRO	Conv Comple	62/478317	29-Mar-2017		
122394-00602	US	CON	Abandoned	16/582688	25-Sep-2019		
122394-00603	US	CON	Abandoned	16/986526	26-Aug-2020		
122394-00604	US	CON	Pending	17/858404	06-Jul-2022		
122394-00620	WO	ORD	Completed	PCT/US2018/025075	29-Mar-2018		
122394-00624	AU	PCT	Pending	2018244442	02-Oct-2019		
122394-00626	CA	PCT	Pending	3058407	27-Sep-2019		
122394-00628	CN	PCT	Published	201880035839.5	29-Nov-2019		

Case Number	Country	Case Type	Application Status	Application Number	Filing Date	Patent Number	Issue Date
122394-00635	EP	PCT	Published	18776747.0	26-Oct-2019		
122394-00643	JP	PCT	Published	2019-553439	27-Sep-2019		
ION-PAIRING (IP) FOR PRODUCING MICROPARTICLES							
122394-01004	US	PRO	Expired	63/115695	19-Nov-2020		
122394-01005	US	PRO	Expired	63/153479	25-Feb-2021		
122394-01020	WO	ORD	Published	PCT/US2021/060105	19-Nov-2021		
CELL-TARGETING PARTICLE COMPOSITION FOR IN VIVO CANCER CELL THERAPY							
122394-02001	US	PRO	Expired	62/780485	17-Dec-2018		

EPLG DOCKET NO.	CTRY	STATUS	APPLICATION NO.	FILING DATE	PATENT NO.	GRANT DATE	TITLE
4246.1000 AU	AU	Issued	2017375793	Dec 12, 2017	2017375793	Jun 17, 2021	Microparticles and Nanoparticles Having Negative Surface Charges
4246.1000 AUD	AU	Pending	2021201342	Dec 12, 2017			Microparticles and Nanoparticles Having Negative Surface Charges
4246.1000 CA	CA	Abandoned	3045669	Dec 12, 2017			Microparticles and Nanoparticles Having Negative Surface Charges
4246.1000 CN	CN	Pending	2017800758247	Dec 12, 2017			Microparticles and Nanoparticles Having Negative Surface Charges
4246.1000 EP	EP	Pending	178801460	Dec 12, 2017			Microparticles and Nanoparticles Having Negative Surface Charges
4246.1000 HKCN	HK	Pending	620200017130	Dec 12, 2017			Microparticles and Nanoparticles Having Negative Surface Charges
4246.1000 JP	JP	Pending	2019551917	Dec 12, 2017			Microparticles and Nanoparticles Having Negative Surface Charges
4246.1000 US	US	Expired	62432810	Dec 12, 2016			Microparticles and Nanoparticles having Negative Surface Charges
4246.1000 US1	US	Abandoned	16619320	Dec 4, 2019			Microparticles and Nanoparticles Having Negative Surface Charges
4246.1000 US2	US	Pending	17408135	Aug 20, 2021			Microparticles and Nanoparticles Having Negative Surface Charges
4246.1000 WO	WO	Completed	PCTUS1765777	Dec 12, 2017			Microparticles and Nanoparticles Having Negative Surface Charges
4246.1003 BE	BE	Issued	20138608674	Dec 4, 2013	2928500	Mar 6, 2019	Microparticles and Nanoparticles Having Negative Surface Charges
4246.1003 CA	CA	Issued	2932532	Dec 4, 2013	2932532	Jun 22, 2021	Microparticles and Nanoparticles Having Negative Surface Charges
4246.1003 CH	CH	Issued	20138608674	Dec 4, 2013	2928500	Mar 6, 2019	Microparticles and Nanoparticles Having Negative Surface Charges

4246.1003 DE	DE	Issued	20138608674	Dec 4, 2013	2928500	Mar 6, 2019	Microparticles and Nanoparticles Having Negative Surface Charges
4246.1003 EP	EP	Issued	20138608674	Dec 4, 2013	2928500	Mar 6, 2019	Microparticles and Nanoparticles Having Negative Surface Charges
4246.1003 EPD	EP	Abandoned	191608520	Dec 4, 2013			Microparticles and Nanoparticles Having Negative Surface Charges
4246.1003 FR	FR	Issued	20138608674	Dec 4, 2013	2928500	Mar 6, 2019	Microparticles and Nanoparticles Having Negative Surface Charges
4246.1003 GB	GB	Issued	20138608674	Dec 4, 2013	2928500	Mar 6, 2019	Microparticles and Nanoparticles Having Negative Surface Charges
4246.1003 IE	IE	Issued	20138608674	Dec 4, 2013	2928500	Mar 6, 2019	Microparticles and Nanoparticles Having Negative Surface Charges
4246.1003 NL	NL	Issued	20138608674	Dec 4, 2013	2928500	Mar 6, 2019	Microparticles and Nanoparticles Having Negative Surface Charges
4246.1003 SE	SE	Issued	20138608674	Dec 4, 2013	2928500	Mar 6, 2019	Microparticles and Nanoparticles Having Negative Surface Charges
4246.1003 US	US	Expired	61733216	Dec 4, 2012			Microparticles and Nanoparticles Having Negative Surface Charges
4246.1003 US1	US	Allowed	14916439	Mar 3, 2016			Microparticles and Nanoparticles Having Negative Surface Charges
4246.1003 US2	US	Issued	16676195	Nov 6, 2019	10780053	Sep 22, 2020	Microparticles and Nanoparticles Having Negative Surface Charges
4246.1003 US3	US	Pending	17879316	Aug 2, 2022			Microparticles and Nanoparticles Having Negative Surface Charges
4246.1003 WO	WO	Completed	PCTUS13073019	Dec 4, 2013			Microparticles and Nanoparticles Having Negative Surface Charges
4246.1004 EP	EP	Abandoned	168377166	Aug 17, 2016			Extremely Small Nanoparticles of Degradable Polymers
4246.1004 JP	JP	Abandoned	2018509813	Aug 17, 2016			Extremely Small Nanoparticles of Degradable Polymers
4246.1004 US	US	Expired	62206003	Aug 17, 2015			Extremely Small Nanoparticles of Degradable Polymers
4246.1004 US1	US	Abandoned	15897371	Feb 15, 2018			Extremely Small Nanoparticles of Degradable Polymers
4246.1004 US2	US	Abandoned	16838137	Apr 2, 2020			Extremely Small Nanoparticles of Degradable Polymers
4246.1004 WO	WO	Completed	PCTUS1647245	Aug 17, 2016			Extremely Small Nanoparticles of Degradable Polymers
4246.1005 US	US	Abandoned		Dec 17, 2018			Cell-Targeting Particle Composition for In Vivo Cancer Cell Therapy
4246.3000 US	US	Expired	62545250	Aug 14, 2017			Microparticle Formulations of Adenosine Receptor Antagonists for Treating Cancer
4246.3000 US1	US	Abandoned	62719121	Aug 16, 2018			Microparticle Formulations of Adenosine Receptor Antagonists for Treating Cancer
4246.3001 AU	AU	Pending	2018317390	Aug 14, 2018			Microparticle Formulations of Adenosine Receptor Antagonists for Treating Cancer
4246.3001 CN	CN	Pending	2018800594063	Aug 14, 2018			Microparticle Formulations of Adenosine Receptor Antagonists for Treating Cancer
4246.3001 EP	EP	Pending	188465660	Aug 14, 2018			Microparticle Formulations of Adenosine Receptor Antagonists for Treating Cancer

4246.3001 JP	JP	Abandoned		Aug 14, 2018			Microparticle Formulations of Adenosine Receptor Antagonists for Treating Cancer
4246.3001 US	US	Expired	62545290	Aug 14, 2017			Particle Formulations of Adenosine Receptor Antagonists for Treating Cancer
4246.3001 US1	US	Issued	16103226	Aug 14, 2018	10702476	Jul 7, 2020	Microparticle Formulations of Adenosine Receptor Antagonists for Treating Cancer
4246.3001 US2	US	Abandoned	16919614	Jul 2, 2020			Microparticle Formulations of Adenosine Receptor Antagonists for Treating Cancer
4246.3001 US3	US	Pending	17867235	Jul 18, 2022			Microparticle Formulations of Adenosine Receptor Antagonists for Treating Cancer
4246.3001 WO	WO	Completed	PCTUS1846644	Aug 14, 2018			Microparticle Formulations of Adenosine Receptor Antagonists for Treating Cancer
4246.3003 US	US	Abandoned	62597669	Dec 12, 2017			Methods for Producing API Loaded Particles Free of Aggregation and Surface API
4246.3003 US1	US	Abandoned	62779081	Dec 13, 2018			Methods for Producing API Loaded Particles Free of Aggregation and Surface API
4246.3004 CA	CA	Pending	3098873	May 10, 2019			Microparticles and Nanoparticles Having Negative Surface Charges
4246.3004 EP	EP	Pending	197999717	May 10, 2019			Microparticles and Nanoparticles Having Negative Surface Charges
4246.3004 HKEP	HK	Pending	620210399551	May 10, 2019			Microparticles and Nanoparticles Having Negative Surface Charges
4246.3004 JP	JP	Pending	2020562668	May 10, 2019			Microparticles and Nanoparticles Having Negative Surface Charges
4246.3004 US	US	Expired	62670204	May 11, 2018			Microparticles and Nanoparticles Having Negative Surface Charges
4246.3004 US1	US	Pending	17093785	Nov 10, 2020			Microparticles and Nanoparticles Having Negative Surface Charges
4246.3004 WO	WO	Completed	PCTUS1931659	May 10, 2019			Microparticles and Nanoparticles Having Negative Surface Charges
4246.3005 US	US	Abandoned	62799719	Jan 31, 2019			Combination Therapy with Microparticle Formulations of Adenosine Receptor Antagonists for Treating Cancer
4246.3005 US1	US	Abandoned	62969226	Feb 3, 2020			Combination Therapy with Microparticle Formulations of Adenosine Receptor Antagonists for Treating Cancer
4246.3006 AU	AU	Pending	2020283956	May 28, 2020			Microparticles and Nanoparticles Having Sulfate Groups on the Surface
4246.3006 CA	CA	Pending	3138430	May 28, 2020			Microparticles and Nanoparticles Having Sulfate Groups on the Surface
4246.3006 CN	CN	Pending	2020800400309	May 28, 2020			Microparticles and Nanoparticles Having Sulfate Groups on the Surface
4246.3006 EP	EP	Pending	208153528	May 28, 2020			Microparticles and Nanoparticles Having Sulfate Groups on the Surface
4246.3006 US	US	Expired	62853302	May 28, 2019			Microparticles and Nanoparticles Having Sulfate Groups on the Surface

4246.3006 US1	US	Pending	17534146	Nov 23, 2021			Microparticles and Nanoparticles Having Sulfate Groups on the Surface
4246.3006 WO	WO	Completed	PCTUS2034842	May 28, 2020			Microparticles and Nanoparticles Having Sulfate Groups on the Surface
4246.3007 US	US	Abandoned	62860068	Jun 11, 2019			Pharmaceutical Composition of Nucleic Acid
4246.3007 US1	US	Abandoned	63038173	Jun 12, 2020			Pharmaceutical Composition of Nucleic Acid
4246.3007 US2	US	Expired	63210824	Jun 15, 2021			Pharmaceutical Composition of Nucleic Acid
4246.3008 US	US	Closed					Particles for Nucleic Acid Delivery
4246.3009 US	US	Abandoned	63035152	Jun 5, 2020			Novel Particle Composition Comprising Polysialic Acid
4246.3009 US1	US	Expired	63208150	Jun 8, 2021			Novel Particle Composition Comprising Polysialic Acid
4246.3009 WO	WO	Pending	PCTUS2232674	Jun 8, 2022			Novel Particle Composition Comprising Sialic Acid Binding Ligand
4246.3010 US	US	Abandoned	63043869	Jun 25, 2020			Methods of Orally Administering Active Agents Using Negatively Charged Microparticles and Nanoparticles
4246.3010 US1	US	Expired	63216102	Jun 29, 2021			Methods of Orally Administering Active Agents Using Negatively Charged Microparticles and Nanoparticles
4246.3011 US	US	Expired	63087454	Oct 5, 2020			Pharmaceutical Composition of Siglec-Binding Agents
4246.3011 US1	US	Pending	17494555	Oct 5, 2021			Pharmaceutical Composition of Siglec-Binding Agents
4246.3011 WO	WO	Pending	PCTUS2153602	Oct 5, 2021			Pharmaceutical Composition of Siglec-Binding Agents
4246.3012 US	US	Expired	63114700	Nov 17, 2020			Novel Drug Delivery Composition and Process for Blood-Brain Barrier Crossing
4246.3012 US1	US	Pending	17527965	Nov 16, 2021			Novel Drug Delivery Composition and Process for Blood-Brain Barrier Crossing
4246.3012 WO	WO	Pending	PCTUS2159539	Nov 16, 2021			Novel Drug Delivery Composition and Process for Blood-Brain Barrier Crossing
4246.3013 US	US	Expired	63114711	Nov 17, 2020			Novel Drug Delivery Composition and Process for Blood-Brain Barrier Crossing
4246.3013 US1	US	Pending	17527974	Nov 16, 2021			Novel Drug Delivery Composition and Process for Blood-Brain Barrier Crossing
4246.3013 WO	WO	Pending	PCTUS2159543	Nov 16, 2021			Novel Drug Delivery Composition and Process for Blood-Brain Barrier Crossing
4246.3014 US	US	Pending	63274130	Nov 1, 2021			Novel Microbeads as Artificial Antigen-Presenting Cells for Immunotherapy
4246.3015 US	US	Pending	63310300	Feb 15, 2022			Novel Pharmaceutical Composition And Methods For Oral Delivery Of Active Therapeutic Ingredients

4246.3016 US	US	Pending	63315350	Mar 1, 2022			Novel Compositions and Methods for the Preparation of Large, Porous Microbeads
4246.3017 US	US	Pending	63337561	May 2, 2022			Polysialic Acid Conjugated Lipids and Uses Thereof
4246.3018 US	US	Pending	63356557	Jun 29, 2022			Novel Lipid Nanoparticle Compositions And Uses Thereof
4246.3019 US	US	Pending	63356777	Jun 29, 2022			Particle Composition of Nucleic Acid

Trademarks:

Zetafinity® - Biodegradable polymer nanoparticles having highly negative surface charges

Cerefinity™ – Polymeric nanoparticles that can cross the blood-brain barrier

Sigfinity™ – Nanoparticles that present Siglec-binding ligands on the surface

Lymphofinity™ – Microparticles and nanoparticles that can be used to activate lymphocytes such as T cells and NK cells in cell therapy.

OralRNA™ – Proprietary nucleic acid particles that may be administered orally.

Domain Names:

Zetafinity – zetafinity.com, zetafinity.net

Cytofinity – cytofinity.com, cytofinity.net

Cererna – cererna.com

Cereceutics – cereceutics.com

Zetasome – zetasome.com, zetasome.net

Cerefinity – cerefinity.com, cerefinity.net

Sigfinity – sigfinity.net

Cytodigm – cytodigm.com

CytoRNA – cytorna.com

Nanommune – nanommune.com

Spherogen – spherogen.com

Scopus – scopusbiosciences.com, scopustx.com, scopus.us